Information Provided By:
Fly News Breaks for January 3, 2019
BSX
Jan 3, 2019 | 07:58 EDT
RBC Capital analyst Glenn Novarro maintained his Top Pick rating and $42 price target on Boston Scientific following the company's "stellar" 2018 that saw its stock price rise 43%. The analyst cites the company's "strong organic revenue and EPS growth, healthy free cash flow, and a deep pipeline" driving the share gains last year, and he expects 2019 to "unfold much like 2018 did". With the new year expected to be highlighted by product launches and enhancements, Novarro believes that the initial "conservative guidance" will position Boston Scientific to beat and raise quarterly earnings, sustaining the premium valuation of its stock.
News For BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.